These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37175725)

  • 21. CPL207280, a Novel G Protein-Coupled Receptor 40/Free Fatty Acid Receptor 1-Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals.
    Bazydlo-Guzenda K; Buda P; Matloka M; Mach M; Stelmach F; Dzida R; Smuga D; Hucz-Kalitowska J; Teska-Kaminska M; Vialichka V; Dubiel K; Kaminska B; Wieczorek M; Pieczykolan J
    Mol Pharmacol; 2021 Oct; 100(4):335-347. PubMed ID: 34349026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold.
    Li Z; Xu X; Hou J; Wang S; Jiang H; Zhang L
    Bioorg Chem; 2018 Apr; 77():429-435. PubMed ID: 29433092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
    Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
    J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPARγ and PPARδ.
    Li Z; Zhou Z; Deng F; Li Y; Zhang D; Zhang L
    Eur J Med Chem; 2018 Nov; 159():267-276. PubMed ID: 30296685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Improving metabolic stability with deuterium: The discovery of HWL-066, a potent and long-acting free fatty acid receptor 1 agonists.
    Liu C; Li Z; Shi W; Li H; Wang N; Dai Y; Liao C; Huang W; Qian H
    Chem Biol Drug Des; 2018 Aug; 92(2):1547-1554. PubMed ID: 29777569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of phenylpropanoic acid derivatives containing polar functionalities as potent and orally bioavailable G protein-coupled receptor 40 agonists for the treatment of type 2 diabetes.
    Mikami S; Kitamura S; Negoro N; Sasaki S; Suzuki M; Tsujihata Y; Miyazaki T; Ito R; Suzuki N; Miyazaki J; Santou T; Kanzaki N; Funami M; Tanaka T; Yasuma T; Momose Y
    J Med Chem; 2012 Apr; 55(8):3756-76. PubMed ID: 22428944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists.
    Wang X; Zhao T; Yang B; Li Z; Cui J; Dai Y; Qiu Q; Qiang H; Huang W; Qian H
    Bioorg Med Chem; 2015 Jan; 23(1):132-40. PubMed ID: 25481394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Free Fatty Acid Receptor 1 (FFAR1) as an Emerging Therapeutic Target for Type 2 Diabetes Mellitus: Recent Progress and Prevailing Challenges.
    Li Z; Xu X; Huang W; Qian H
    Med Res Rev; 2018 Mar; 38(2):381-425. PubMed ID: 28328012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis and biological activity of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists.
    Li Z; Wang X; Xu X; Yang J; Xia W; Zhou X; Huang W; Qian H
    Bioorg Med Chem; 2015 Nov; 23(22):7158-64. PubMed ID: 26482570
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and structure-activity relationship studies of GPR40 agonists containing amide linker.
    Chen T; Ning M; Ye Y; Wang K; Leng Y; Shen J
    Eur J Med Chem; 2018 May; 152():175-194. PubMed ID: 29705709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthetic GPR40/FFAR1 agonists: An exhaustive survey on the most recent chemical classes and their structure-activity relationships.
    Paul A; Nahar S; Nahata P; Sarkar A; Maji A; Samanta A; Karmakar S; Maity TK
    Eur J Med Chem; 2024 Jan; 264():115990. PubMed ID: 38039791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
    Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
    Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of Potent and Orally Bioavailable GPR40 Full Agonists Bearing Thiophen-2-ylpropanoic Acid Scaffold.
    Li H; Huang Q; Chen C; Xu B; Wang HY; Long YQ
    J Med Chem; 2017 Apr; 60(7):2697-2717. PubMed ID: 28277660
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple mechanisms of GW-9508, a selective G protein-coupled receptor 40 agonist, in the regulation of glucose homeostasis and insulin sensitivity.
    Ou HY; Wu HT; Hung HC; Yang YC; Wu JS; Chang CJ
    Am J Physiol Endocrinol Metab; 2013 Mar; 304(6):E668-76. PubMed ID: 23341496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold.
    Li Z; Liu C; Yang J; Zhou J; Ye Z; Feng D; Yue N; Tong J; Huang W; Qian H
    Eur J Med Chem; 2019 Oct; 179():608-622. PubMed ID: 31279294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and biological evaluation of novel dual FFA1 and PPARδ agonists possessing phenoxyacetic acid scaffold.
    Zhou Z; Cai Z; Zhang C; Yang B; Chen L; He Y; Zhang L; Li Z
    Bioorg Med Chem; 2022 Feb; 56():116615. PubMed ID: 35051813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antidiabetic Activity of Dihydropyrimidine Scaffolds and Structural Insight by Single Crystal X-ray Studies.
    Bairagi KM; Younis NS; Emeka PM; Sangtani E; Gonnade RG; Venugopala KN; Alwassil OI; Khalil HE; Nayak SK
    Med Chem; 2020; 16(7):996-1003. PubMed ID: 31880253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current status of GPR40/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review.
    Li Z; Zhou Z; Zhang L
    Expert Opin Ther Pat; 2020 Jan; 30(1):27-38. PubMed ID: 31771391
    [No Abstract]   [Full Text] [Related]  

  • 39. Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)/PPARδ agonists as potential anti-diabetic agents.
    Li Z; Hu L; Wang X; Zhou Z; Deng L; Xu Y; Zhang L
    Bioorg Chem; 2019 Nov; 92():103254. PubMed ID: 31518760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent Advances in Development of GPR40 Modulators (FFA1/FFAR1): An Emerging Target for Type 2 Diabetes.
    Sharma N; Bhagat S; Chundawat TS
    Mini Rev Med Chem; 2017; 17(11):947-958. PubMed ID: 28117025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.